心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2020 AHA科学声明：新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用

2020-09-28 美国心脏协会 Circulation . 2020 Sep 28

降糖药物

2020年9月，美国心脏协会(AHA)发布了新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用的共识声明。慢性肾脏病患者合并2型糖尿病是一个重大的公众卫生健康问题，可导致严重的心血管和肾脏不良结局。本文

中文标题：

2020 AHA科学声明：新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用

英文标题：

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association

发布机构：

美国心脏协会

发布日期：

2020-09-28

简要介绍：

2020年9月，美国心脏协会(AHA)发布了新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用的共识声明。慢性肾脏病患者合并2型糖尿病是一个重大的公众卫生健康问题，可导致严重的心血管和肾脏不良结局。本文主要总结了当前SGLT2抑制剂以及GLP-1 受体激动剂在CKD合并T2D患者中的心肾保护作用。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 AHA科学声明：新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b93001c00198e712, title=2020 AHA科学声明：新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用, enTitle=Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association, guiderFrom=Circulation . 2020 Sep 28, authorId=0, author=, summary=2020年9月，美国心脏协会(AHA)发布了新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用的共识声明。慢性肾脏病患者合并2型糖尿病是一个重大的公众卫生健康问题，可导致严重的心血管和肾脏不良结局。本文, cover=https://img.medsci.cn/2020106/1601997012747_2020535.jpg, journalId=0, articlesId=null, associationId=60, associationName=美国心脏协会, associationIntro=美国心脏协会（AHA，American Heart Association）是心脏病学领域比较正要的学会之一，致力于心脏病和卒中的预防与治疗，提供相关继续教育、流行病学年度报告。每年举办学术年会报道中的的临床试验结果等，有官方杂志《美国心脏协会杂志》，提供心血管疾病和卒中相关的指南及专家共识，更新的比较快。, copyright=0, guiderPublishedTime=Mon Sep 28 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年9月，美国心脏协会(AHA)发布了新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用的共识声明。慢性肾脏病患者合并2型糖尿病是一个重大的公众卫生健康问题，可导致严重的心血管和肾脏不良结局。本文主要总结了当前SGLT2抑制剂以及GLP-1 受体激动剂在CKD合并T2D患者中的心肾保护作用。</p> </div> </div> </div>, tagList=[TagDto(tagId=5279, tagName=降糖药物)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=5279, guiderKeyword=降糖药物, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5878, appHits=366, showAppHits=0, pcHits=820, showPcHits=5512, likes=0, shares=26, comments=17, approvalStatus=1, publishedTime=Wed Oct 07 00:06:44 CST 2020, publishedTimeString=2020-09-28, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Oct 06 23:10:28 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Thu Dec 28 10:58:23 CST 2023, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 AHA科学声明：新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用.pdf)])
2020 AHA科学声明：新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=921916, encodeId=92819219163e, content=GLP1和SGLT2都是好药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b355457759, createdName=ms7000002141506965, createdTime=Mon Feb 01 14:12:12 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900994, encodeId=2c1f90099429, content=真的很火热, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2f5437117, createdName=ms6000001989687174, createdTime=Sat Nov 21 15:34:02 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900363, encodeId=88ca90036337, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900362, encodeId=97ce900362b2, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:14 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892624, encodeId=924b892624e1, content=SGLT2很火啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Sat Oct 17 11:09:30 CST 2020, time=2020-10-17, status=1, ipAttribution=)]
    2021-02-01 ms7000002141506965

    GLP1和SGLT2都是好药

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=921916, encodeId=92819219163e, content=GLP1和SGLT2都是好药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b355457759, createdName=ms7000002141506965, createdTime=Mon Feb 01 14:12:12 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900994, encodeId=2c1f90099429, content=真的很火热, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2f5437117, createdName=ms6000001989687174, createdTime=Sat Nov 21 15:34:02 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900363, encodeId=88ca90036337, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900362, encodeId=97ce900362b2, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:14 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892624, encodeId=924b892624e1, content=SGLT2很火啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Sat Oct 17 11:09:30 CST 2020, time=2020-10-17, status=1, ipAttribution=)]
    2020-11-21 ms6000001989687174

    真的很火热

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=921916, encodeId=92819219163e, content=GLP1和SGLT2都是好药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b355457759, createdName=ms7000002141506965, createdTime=Mon Feb 01 14:12:12 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900994, encodeId=2c1f90099429, content=真的很火热, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2f5437117, createdName=ms6000001989687174, createdTime=Sat Nov 21 15:34:02 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900363, encodeId=88ca90036337, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900362, encodeId=97ce900362b2, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:14 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892624, encodeId=924b892624e1, content=SGLT2很火啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Sat Oct 17 11:09:30 CST 2020, time=2020-10-17, status=1, ipAttribution=)]
    2020-11-19 czfsyy2010

    为糖肾带来了新的希望

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=921916, encodeId=92819219163e, content=GLP1和SGLT2都是好药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b355457759, createdName=ms7000002141506965, createdTime=Mon Feb 01 14:12:12 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900994, encodeId=2c1f90099429, content=真的很火热, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2f5437117, createdName=ms6000001989687174, createdTime=Sat Nov 21 15:34:02 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900363, encodeId=88ca90036337, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900362, encodeId=97ce900362b2, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:14 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892624, encodeId=924b892624e1, content=SGLT2很火啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Sat Oct 17 11:09:30 CST 2020, time=2020-10-17, status=1, ipAttribution=)]
    2020-11-19 czfsyy2010

    为糖肾带来了新的希望

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=921916, encodeId=92819219163e, content=GLP1和SGLT2都是好药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b355457759, createdName=ms7000002141506965, createdTime=Mon Feb 01 14:12:12 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900994, encodeId=2c1f90099429, content=真的很火热, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2f5437117, createdName=ms6000001989687174, createdTime=Sat Nov 21 15:34:02 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900363, encodeId=88ca90036337, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:35 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900362, encodeId=97ce900362b2, content=为糖肾带来了新的希望, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335f1378866, createdName=czfsyy2010, createdTime=Thu Nov 19 08:28:14 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892624, encodeId=924b892624e1, content=SGLT2很火啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/a58cd132de154a358698b0c694c6c5d6/76ce68206b51445889f5b9b093729f77.png, createdBy=f4ac1650319, createdName=1ddc6cfam23(暂无匿称), createdTime=Sat Oct 17 11:09:30 CST 2020, time=2020-10-17, status=1, ipAttribution=)]
    2020-10-17 1ddc6cfam23(暂无匿称)

    SGLT2很火啊

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2017 KDA立场声明：降糖药物治疗成人2型糖尿病

韩国糖尿病协会(KDA,Korean Diabetes Association) · 2017-10-23

拓展阅读

2017 KDA立场声明：降糖药物治疗成人2型糖尿病

韩国糖尿病协会(KDA,Korean Diabetes Association) · 2017-10-23

【中文译文】2020 AHA科学声明：新型降糖药物对糖尿病和慢性肾病患者的心肾保护作用

美国心脏协会(AHA,American Heart Association) · 2020-09-28